TGFB1 and scleroderma: That dasatinib may possess potential efficacy against profibrotic TGF-β signalling in vivo was suggested by preclinical studies, in which dasatinib treatment of scleroderma and normal fibroblasts led to decreased production of extracellular matrix proteins [28].